It is very uncertain whether boost changes late toxicity, pBRA compared with no boost (very low certainty).
Boost may leads to higher cosmesis, panel scored: fair or poor compared with no boost (low certainty).
Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).
Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).
Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).
Summary of findings: Non‐intensive showed no clear difference in disease‐free survival compared with intensive follow‐up (low certainty).
Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).
Summary of findings: Decentralised showed no clear difference in disease‐free survival compared with centralised follow‐up (moderate certainty).
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
Hypofractionated radiation therapy showed no clear difference in local recurrence‐free survival (LR‐FS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in cosmesis compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in mortality at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in late subcutaneous toxicity compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in breast cancer‐specific survival (BC‐SS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in relapse‐free survival (RFS) at 10 years compared with conventionally fractionated radiation therapy (moderate certainty).